Amphastar Pharmaceuticals (AMPH) Net Income towards Common Stockholders (2013 - 2026)

Amphastar Pharmaceuticals' Net Income towards Common Stockholders history runs 14 years deep, the most recent figure standing at $6.4 million for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders fell 74.61% year-over-year to $6.4 million; the TTM figure through Mar 2026 stood at $102.4 million (down 27.71% YoY), while the FY2025 annual figure was $121.2 million, down 24.26% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at $6.4 million, down from $47.6 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $49.6 million in Q3 2023, with the low at -$145.2 million in Q4 2023.
• The 5-year median for Net Income towards Common Stockholders is $26.8 million (2023), against an average of $19.9 million.
• The sharpest annual moves came in 2022 and 2023: Net Income towards Common Stockholders surged 530.36% in 2022, then sank 527.58% in 2023.
• Amphastar Pharmaceuticals' Net Income towards Common Stockholders stood at $34.0 million in 2022, then tumbled by 527.58% to -$145.2 million in 2023, then surged by 126.14% to $38.0 million in 2024, then climbed by 25.34% to $47.6 million in 2025, then tumbled by 86.51% to $6.4 million in 2026.
• Business Quant data shows AMPH's Net Income towards Common Stockholders at $6.4 million in Q1 2026, $47.6 million in Q4 2025, and $17.3 million in Q3 2025.